Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.013 | 0.5648 | 1 | |
Echinococcus granulosus | thymidylate synthase | 0.013 | 0.5648 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.013 | 0.5648 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.013 | 0.5648 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0062 | 0.0052 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.013 | 0.5648 | 1 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0183 | 1 | 0.5 |
Brugia malayi | hypothetical protein | 0.0062 | 0.0052 | 0.0092 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0183 | 1 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.013 | 0.5648 | 0.5 |
Brugia malayi | thymidylate synthase | 0.013 | 0.5648 | 1 |
Mycobacterium ulcerans | thymidylate synthase | 0.013 | 0.5648 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0183 | 1 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0183 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.013 | 0.5648 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0183 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 3446 nM | Evaluated for their growth inhibition (IC50) against P. falciparum clones with mutant strain (T9/94) | ChEMBL. | 10893311 |
IC50 (functional) | = 3446 nM | Evaluated for their growth inhibition (IC50) against P. falciparum clones with mutant strain (T9/94) | ChEMBL. | 10893311 |
IC50 (functional) | = 8223 nM | Growth inhibition (IC50) against P. falciparum clones with wild-type (TM4/8.2) | ChEMBL. | 10893311 |
IC50 (functional) | = 8223 nM | Growth inhibition (IC50) against P. falciparum clones with wild-type (TM4/8.2) | ChEMBL. | 10893311 |
IC50 ratio (functional) | = 0.42 | Selectivity ratio of growth inhibition values of wild-type (TM4/8.2) and mutant (T9/94) clones of P. falciparum | ChEMBL. | 10893311 |
IC50 ratio (functional) | = 0.42 | Selectivity ratio of growth inhibition values of wild-type (TM4/8.2) and mutant (T9/94) clones of P. falciparum | ChEMBL. | 10893311 |
Ki (binding) | = 167 nM | Evaluated for inhibition constant (Ki wt) against Wild-type dihydrofolate reductase of Plasmodium falciparum | ChEMBL. | 10893311 |
Ki (binding) | = 167 nM | Evaluated for inhibition constant (Ki wt) against Wild-type dihydrofolate reductase of Plasmodium falciparum | ChEMBL. | 10893311 |
Ki (binding) | = 1460 nM | Inhibition constant (Ki mut) against A16V+S108T Mutant DHFRs of Plasmodium falciparum | ChEMBL. | 10893311 |
Ki (binding) | = 1460 nM | Inhibition constant (Ki mut) against A16V+S108T Mutant DHFRs of Plasmodium falciparum | ChEMBL. | 10893311 |
Ratio (binding) | = 8.7 | Ratio of inhibitory constant of mutant by wildtype DHFRs of P. falciparum | ChEMBL. | 10893311 |
Ratio (binding) | = 8.7 | Ratio of inhibitory constant of mutant by wildtype DHFRs of P. falciparum | ChEMBL. | 10893311 |
Relative activity (binding) | = 1.11 | Evaluated for activity of compound relative to Cycloguanil | ChEMBL. | 10893311 |
Relative activity (binding) | = 111 | Evaluated for activity of relative to Cycloguanil | ChEMBL. | 10893311 |
Relative activity (binding) | = 1.11 | Evaluated for activity of compound relative to Cycloguanil | ChEMBL. | 10893311 |
Relative activity (binding) | = 111 | Evaluated for activity of relative to Cycloguanil | ChEMBL. | 10893311 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 10893311 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.